CTT PHARMACEUTICAL (CTTH) CEO Buys 10,100 Shares

What Happened
The company's CEO and director reported a purchase of 10,100 shares of CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH). The Form 4 shows an acquisition at $0.04 per share for a total cash outlay of roughly $455. The filing lists the transaction code "P" (purchase), reported as an open-market or private purchase.

Key Details

• Transaction date: 2026-09-22 (Form 4 filed same day). Period of report lists 2026-09-18.
• Price and amount: 10,100 shares at $0.04 each; total ≈ $455.
• Transaction code: P = Purchase (open-market or private purchase as reported).
• Shares owned after the transaction: not provided in the details you supplied (check the full Form 4 for post-transaction holdings).
• Footnotes / plans: no 10b5-1 plan, tax-withholding, or other footnotes were included in the information provided.
• Timeliness: Filing appears timely — the Form 4 was filed within the SEC’s two-business-day window (transaction 9/18, filing 9/22).

Context
This is a small-dollar insider purchase. Purchases by insiders can be interpreted as a modest positive signal, but given the low dollar amount (~$455), it represents a very small stake and should be weighed accordingly with other information about the company. For full ownership details and any additional disclosures, review the complete Form 4 filing (Accession: 0001035422-26-000013).